bioengineer.org
/1 day ago
Dostarlimab Achieves Complete Response in Rare SMARCA4-Deficient Metastatic Uterine Sarcoma Case
A patient with metastatic SMARCA4-deficient undifferentiated uterine sarcoma achieved a 42-month complete response following dostarlimab therapy.